TNDM · Tandem Diabetes Care Inc
$16.31
-0.26 (-1.57%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$1.09B
Shares
69.58M
Volume · Sep 30
2.2M
Avg daily vol (3M)
1.94M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.31
Open$16.63
Day$16.00–16.68
52W close$12.14–28.26
Avg vol 30d1.9M
Short int12.5M · 17.9% float · 7.9d
Short vol51%
Last earningsAug 6, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.04B
Trailing 12 months
Net income (TTM)
−$63.31M
Trailing 12 months
Revenue growth YoY
+5.8%
Year over year
Operating margin
-4.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.9%
Year over year · more shares
Price change (1Y)
+40.5%
Trailing year
Short interest
17.9%
Latest settlement · 7.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−16%
below
Price vs 50-day avg
−17%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
26%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−23%
trailing
6-month return
−17%
trailing
YTD return
−26%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $20 › 200d $19 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +47 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.93% of float · ▲ +6.1% MoM · 7.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
275 holders — mid 3-yr range
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
54%
expanding
EPS growth
−107%
Y/Y
Free cash flow
$-29.7M
Balance sheet
$69.0M
net debt
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Sales
· year ending December 31, 2026
Initiated
$1.07B – $1.09B
prior FY $1.01B
midpoint +5.9% Y/Y
U.S. sales
· year ending December 31, 2026
Initiated
$730M – $745M
International sales
· year ending December 31, 2026
Initiated
$335M – $340M
Gross margin
· year ending December 31, 2026
Initiated
56% – 57%
Adjusted EBITDA margin
· year ending December 31, 2026
Non-GAAP
Initiated
5% – 6%
Non-cash charges included in cost of goods sold and operating ex
· year ending December 31, 2026
Initiated
$85M
Non-cash, stock-based compensation expense
· year ending December 31, 2026
Initiated
$65M
Depreciation and amortization expense
· year ending December 31, 2026
Initiated
$20M
Guided vs delivered
· last 3 settled
Worldwide sales
full year 2021
guided $685M – $695M
$702.8M
Beat +1.9%
Worldwide sales
full year of 2020
guided $465M – $475M
$498.83M
Beat +6.1%
Worldwide sales
the second quarter
guided at least $85M
$109.24M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−16%
Bearish
Price vs 50-day avg
−17%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
26%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $20 › 200d $19 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +47 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.93% of float · ▲ +6.1% MoM · 7.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
275 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $12
Now $16 · 26%
Range high $28
vs 200-day avg -16%
vs 50-day avg -17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TNDM
this stock
Tandem Diabetes Care Inc
|
$1.09B | -25.8% | +7.9% | — | 17.9% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TNDM | -0.4% | -23.4% | -17.1% | -25.9% | -25.8% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +0.2% | -23.5% | -29.3% | -25.3% | -37.6% |
Key facts
CIK
1438133
CUSIP
875372203
13F (30d)
14 filings
8 filers
Visit website
Investor relations